(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
----------
AIM - WINNERS
----------
K3 Capital Group PLC, up 10% at 258.36 pence, 12-month range 205.00p-380.00p. The professional advisory services firm says its annual results are likely to exceed market expectations. K3 says for the year ended May 31, revenue is expected to grow by around 43% to GBP77.5 million, from GBP47.2 million the year before. Adjusted earnings before interest, tax, depreciation and amortisation are expected to be 24% higher at GBP19.5 million from GBP15.7 million. The figures exceed market expectations, which according to Numis sit at GBP63.5 million for revenue and GBP18.2 million in Ebitda.
----------
Oxford Biodynamics PLC, up 8.0% at 17.55p, 12-month range 15.50p-62.80p. Shares in biotech firm move off 12-month lows after its checkpoint inhibitor response test becomes available in the UK. The EpiSwitch CiRT blood test predicts a patient's likely response to immune checkpoint inhibitor therapies, with high levels of sensitivity, specificity, accuracy and negative predictive value across 15 cancer indications where ICI treatments are approved. The test is now available to private physicians in the UK online. Oxford says the appeal of the test for the UK's National Health Service, given the high rates of inefficacy of ICI treatments, and their high costs.
----------
Midatech Pharma PLC, up 7.8% at 9.43p, 12-month range 8.16p-38.00p. The biotechnology company receives Orphan Medicinal Product designation from the European Medicines Agency for the development programme for MTX110. Explains that the designation offers protocol development assistance, a reduction in fees and market exclusivity upon the successful approval of the drug.
----------
AIM - LOSERS
----------
Morses Club PLC, down 24% at 7.91p, 12-month range 4.50p-95.00p. The doorstep lender warns that an increase in complaints could badly affect its trading performance for the first half of its financial year. Morses says that its home collected credit division has seen a rise in complaints submitted by claims management firms, leading to claim volumes returning to the level seen in February. Should this level be sustained, Morses expects the cost of the complaints could hurt its trading performance for the six months ending August 31.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Oxford Biodyn (OBD)